Latest news with #Mandolin
Yahoo
25-06-2025
- Business
- Yahoo
Mandolin Raises $40M to Improve Access to Life-Saving Therapies for Diseases like Cancer and Alzheimer's Using AI Agents
Mandolin brings AI teammates to healthcare, accelerating patient access and cutting operational cost SAN FRANCISCO, June 25, 2025--(BUSINESS WIRE)--Mandolin, the leading AI automation platform for specialty drug access, announced that it has raised $40 million in funding from Greylock Partners, SignalFire, Maverick, SV Angel, along with Jerry Yang (co-founder of Yahoo!) and Guillermo Rauch (CEO of Vercel). Founded by repeat entrepreneurs Will Yin (CEO) and Rohit Rustagi (COO), Mandolin is used by many of the nation's largest infusion providers, pharmacies, and health systems. Recent advances in drug development have caused an explosion of specialty therapies addressing rare and chronic conditions like cancers, immune disorders, and Alzheimer's. Specialty therapies represented $250 billion in drug spend in 2024 and are expected to reach $1.5 trillion in drug spend in eight years. They are also 75% of the drugs in the FDA's approval pipeline. Unlike traditional drugs bought at retail pharmacies, these drugs are often administered by healthcare professionals in a clinical setting. They are also processed through an arduous administrative process established by insurance companies, often delaying patients' access to life-changing treatments by weeks. "Insurance companies make the approval process challenging for specialty medications. Infusion providers, pharmacies, and health systems spend an excessive amount of manpower on basic tasks like checking insurance coverage, submitting prior authorizations, or verifying reimbursement amounts, which take weeks of time per prescription and lead to millions in bad debt," said Will Yin, CEO and co-founder of Mandolin. "Leveraging the latest advancements in AI, we saw an opportunity to build autonomous agents that can tackle these workflows for providers in minutes and more reliably." Mandolin's founders, Will Yin and Rohit Rustagi, have a strong passion and vision for improving our healthcare system using AI. After initially pursuing academic research on conditions like Alzheimer's and cancer that have impacted their families, they saw first-hand the difficulty and delays associated with specialty drug approvals. Recognizing how broken the healthcare system was for accessing these treatments, combined with the insight that large language models could now reason like the best performing employees, they joined forces to start Mandolin in 2024. Mandolin's AI platform automates the end-to-end administrative side of infused and injected drug delivery for providers. Mandolin's AI agents act just like your best employees, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows. They integrate into existing electronic health records (EHRs), payer portals, and manufacturer hubs. By centralizing operational logic and real-time decision-making into a single platform, Mandolin dramatically reduces time-to-treatment from weeks to days, lowers back-office costs, improves billing accuracy, and unlocks visibility into drug usage and patient pathways. Since launching its product in January, the industry has been quick to respond. Mandolin is already working with many of the largest US infusion providers, pharmacies, and health systems, including Vivo Infusion, FlexCare Infusion, OI Infusion, TwelveStone Health Partners, and Amber Specialty Pharmacy. Across customers, Mandolin is deployed in over 700 clinic locations and serves over 250,000 new patients a year. "Mandolin has been nothing short of transformational for our business. Tasks that used to take days, now happen in under an hour," said Cannon Loughry, COO of TwelveStone. "We've automated key workflows across billing, patient communication, and insurance verification, driving real gains in terms of better cash flow and the reduction of headcount as we scale. Mandolin acts as an AI employee integrated directly into our core systems. We just tell it what needs to get done, and it does the work." "Will and Rohit saw the opportunity to bring agentic AI into a system drowning in paperwork, delays, and revenue leakage," said Jerry Chen, partner at Greylock Partners. "Despite being founded a year ago, Mandolin is already proving that AI agents can unlock faster treatment for patients and far better economics for providers. We at Greylock are thrilled to partner with them on their journey." About Mandolin Mandolin is the leading AI automation platform for specialty drug access. The company's AI agents act just like a best employee, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows. Backed by Greylock, SignalFire, Maverick, and SV Angel, Mandolin works with the largest consolidated infusion providers, specialty and home infusion pharmacies, and health systems in the country. For more information, visit: View source version on Contacts Media Contact: Mandolin PR — press@
Business Wire
25-06-2025
- Business
- Business Wire
Mandolin Raises $40M to Improve Access to Life-Saving Therapies for Diseases like Cancer and Alzheimer's Using AI Agents
SAN FRANCISCO--(BUSINESS WIRE)-- Mandolin, the leading AI automation platform for specialty drug access, announced that it has raised $40 million in funding from Greylock Partners, SignalFire, Maverick, SV Angel, along with Jerry Yang (co-founder of Yahoo!) and Guillermo Rauch (CEO of Vercel). Founded by repeat entrepreneurs Will Yin (CEO) and Rohit Rustagi (COO), Mandolin is used by many of the nation's largest infusion providers, pharmacies, and health systems. Recent advances in drug development have caused an explosion of specialty therapies addressing rare and chronic conditions like cancers, immune disorders, and Alzheimer's. Specialty therapies represented $250 billion in drug spend in 2024 and are expected to reach $1.5 trillion in drug spend in eight years. They are also 75% of the drugs in the FDA's approval pipeline. Unlike traditional drugs bought at retail pharmacies, these drugs are often administered by healthcare professionals in a clinical setting. They are also processed through an arduous administrative process established by insurance companies, often delaying patients' access to life-changing treatments by weeks. 'Insurance companies make the approval process challenging for specialty medications. Infusion providers, pharmacies, and health systems spend an excessive amount of manpower on basic tasks like checking insurance coverage, submitting prior authorizations, or verifying reimbursement amounts, which take weeks of time per prescription and lead to millions in bad debt,' said Will Yin, CEO and co-founder of Mandolin. 'Leveraging the latest advancements in AI, we saw an opportunity to build autonomous agents that can tackle these workflows for providers in minutes and more reliably.' Mandolin's founders, Will Yin and Rohit Rustagi, have a strong passion and vision for improving our healthcare system using AI. After initially pursuing academic research on conditions like Alzheimer's and cancer that have impacted their families, they saw first-hand the difficulty and delays associated with specialty drug approvals. Recognizing how broken the healthcare system was for accessing these treatments, combined with the insight that large language models could now reason like the best performing employees, they joined forces to start Mandolin in 2024. Mandolin's AI platform automates the end-to-end administrative side of infused and injected drug delivery for providers. Mandolin's AI agents act just like your best employees, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows. They integrate into existing electronic health records (EHRs), payer portals, and manufacturer hubs. By centralizing operational logic and real-time decision-making into a single platform, Mandolin dramatically reduces time-to-treatment from weeks to days, lowers back-office costs, improves billing accuracy, and unlocks visibility into drug usage and patient pathways. Since launching its product in January, the industry has been quick to respond. Mandolin is already working with many of the largest US infusion providers, pharmacies, and health systems, including Vivo Infusion, FlexCare Infusion, OI Infusion, TwelveStone Health Partners, and Amber Specialty Pharmacy. Across customers, Mandolin is deployed in over 700 clinic locations and serves over 250,000 new patients a year. "Mandolin has been nothing short of transformational for our business. Tasks that used to take days, now happen in under an hour,' said Cannon Loughry, COO of TwelveStone. 'We've automated key workflows across billing, patient communication, and insurance verification, driving real gains in terms of better cash flow and the reduction of headcount as we scale. Mandolin acts as an AI employee integrated directly into our core systems. We just tell it what needs to get done, and it does the work.' 'Will and Rohit saw the opportunity to bring agentic AI into a system drowning in paperwork, delays, and revenue leakage,' said Jerry Chen, partner at Greylock Partners. 'Despite being founded a year ago, Mandolin is already proving that AI agents can unlock faster treatment for patients and far better economics for providers. We at Greylock are thrilled to partner with them on their journey.' About Mandolin Mandolin is the leading AI automation platform for specialty drug access. The company's AI agents act just like a best employee, completing tasks like reasoning about clinical policies, calling payers, parsing faxes and handwritten notes, and making decisions across entire workflows. Backed by Greylock, SignalFire, Maverick, and SV Angel, Mandolin works with the largest consolidated infusion providers, specialty and home infusion pharmacies, and health systems in the country. For more information, visit:
Miami Herald
18-02-2025
- Business
- Miami Herald
One of New York's popular Italian restaurants just opened in Miami with a stunning garden
Carlos Suarez, founder of the popular New York restaurant Rosemary's, grew up in Coral Gables in the 1990s, but after college gravitated to the northeast. And when it came time to open his first restaurant — named for his mother — he opened it in the West Village, then went on to expand in Tokyo, the East Village and Midtown Manhattan. Now, 13 years later, Rosemary's has finally made it to Miami. The Italian restaurant from Suarez's Casa Nela hospitality group is now open in Wynwood. Though he took his time, Suarez said that he has been working to expand south for awhile. 'I've been back here many times since I moved away, but I've always been checking in with Miami, because I have such fond memories of growing up here,' he says. 'But in the past, I always recognized that Miami was probably more interested in flashy, big ticket, big night out stuff that we don't do.' Miami, of course, has changed dramatically recently, a shift fueled at first by the pandemic and an influx of new residents, then by the arrival of the Michelin Guide in 2022, followed by an explosion of development, particularly in Wynwood. But Suarez first started paying closer attention as early as 2007, when Michael's Genuine opened in the Design District, and 2009, when Mandolin Aegean Bistro joined it on the other side of the soon-to-be upscale neighborhood. 'Seeing the success of Michael's and Mandolin started to plant the seed that maybe the market would mature to a place where quality neighborhood restaurants would be celebrated,' Suarez says. By 2014, he was looking at possible spaces for a Miami Rosemary's. Built on the site of a former shoe warehouse and empty lot on Northwest 25th Street, the 7,000-square foot restaurant has an airy indoor dining room with high ceilings with lights strung from them and homey touches like a brick wall and a display of copper pans, an homage to Suarez's Cuban father Raul, who loved his own copper cookware. There's greenery on the indoor tables and everywhere in the outdoor dining area. Designed by New York firm Dekar Design, the entrance welcomes diners with sculpted bougainvillea, and small garden beds are scattered throughout the space. Created with Little River Cooperative's help, the beds of greens, vegetables, herbs and edible flowers are used in several dishes. The gardens are a nod to Suarez's English mother and her vegetable garden in Lucca, Italy (the Suarezes spent about 20 years in South Florida as a family but also lived in Asia and Europe). The New York locations of Rosemary have rooftop gardens, too. Having lived in South Florida, Suarez is well aware of Miami's wet summers, and his team will be installing retractable awnings over much of the outdoor dining area and the outdoor bar. 'There's the success of Mandolin to point to as a restaurant that's thrived despite being 90 percent outside,' Suarez says. 'But we are taking steps to enclose when necessary.' The kitchen is helmed by executive chef Craig Giunta, a former chef at Miami Beach's beloved Macchialina who also worked at Mother Wolf and Concours Club. Rosemary, obviously, is a special theme on the menu: Don't skip the rosemary foccaccia or spectacular rosemary potatoes, and note that the water is also infused with fresh sprigs of the herb. The menu leans toward pasta and seafood , with a few specialties only available in Miami, like the bluefin tuna crudo with citrus, coriander, basil and fennel from the garden; linguini with Florida rock shrimp, lemon bomba chilis and garlic; and Heritage porchetta with zucchini salad and Calabrian date hot sauce. Other choices include orecchiette with sausage, broccoli rabe, Fresno chili and Parmigiano and pappardelle verde with veal Bolognese, a white Bolognese sauce. Dessert options include an olive oil cake draped in blueberry compote, and hot, crispy Bombolini, Italian doughnuts served with a Nutella sauce. Suarez says that despite the number of Italian restaurants in the area — the swanky, nightclub-esque Sparrow Italia just down the street, and Pasta and Otto & Pepe not far away, for example — thanks to Miami diners' passion for food, the neighborhood can sustain multiple restaurants and that the gorgeous outdoor area sets Rosemary's apart. 'The menu is probably similar to places like Pasta and Otto & Pepe, but we brought a garden. We're really trying to lean into local sourcing and growing our produce,' he says. 'We're low key, high quality. We want to prove great dining experiences don't need to be expensive or flashy, and they definitely don't need to be expensive.' Rosemary's Where: 322 NW 25th St., Miami Hours: 5-10 p.m. Sunday-Thursday; 5-11 p.m. Friday-Saturday Reservations: Resy More information: or 305-486-2424
